Literature DB >> 8252502

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.

P Iversen1, F Rasmussen, P Klarskov, I J Christensen.   

Abstract

In a multicenter trial conducted by the Danish Prostatic Cancer Group, 264 patients with advanced prostate cancer were randomized either to undergo bilateral orchiectomy or to receive combination treatment with goserelin acetate and flutamide. This report is an update of that study, covering a median follow-up for survival of 57 months. Of 262 patients who were evaluated, 208 have died. As noted in earlier analyses of this study, no differences in time to progression and cause-specific and overall survival could be identified between the two treatment groups. In conclusion, the combination of goserelin and flutamide was not clinically superior to bilateral orchiectomy in the treatment of advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252502     DOI: 10.1002/1097-0142(19931215)72:12+<3851::aid-cncr2820721717>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Authors:  Steven B Zeliadt; David F Penson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Hormonal therapy in prostate cancer: historical approaches.

Authors:  E David Crawford
Journal:  Rev Urol       Date:  2004

Review 3.  Clinical pharmacokinetics of goserelin.

Authors:  I D Cockshott
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 4.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

5.  Controversies in the management of advanced prostate cancer.

Authors:  C J Tyrrell
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

Review 6.  Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.

Authors:  Lucie-Marie Scailteux; Florian Naudet; Quentin Alimi; Sébastien Vincendeau; Emmanuel Oger
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

7.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.